[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
The purpose of this study is to assess \[18F\] -fluciclatide as a biomarker of response to pazopanib and to evaluate the efficacy and safety of the combination of pazopanib and paclitaxel in platinum-resistant ovarian cancer patients.
Ovarian Neoplasm
DRUG: Pazopanib and paclitaxel
Assessment of change in [18F]-fluciclatide retention parameters following 1 week of pazopanib treatment, Semi-quantitative standardized uptake value and fully quantitative net irreversible plasma to tumour transfer constant, 1 week
The proportion of women who experience side effects from the combination of paclitaxel and pazopanib, Core study assessments including physical examination, vital signs, ECG, and adverse event reporting, 12 months|The proportion of patients responding to combination paclitaxel and pazopanib, 12 months
The purpose of this study is to assess \[18F\] -fluciclatide as a biomarker of response to pazopanib and to evaluate the efficacy and safety of the combination of pazopanib and paclitaxel in platinum-resistant ovarian cancer patients.